Sign in
Active, not recruitingNo phase

US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism

Key facts

Who runs it
Adient Medical
Where
Aurora and Indianapolis, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
854 people, planned
Started
27 Jan 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Adient absorbable filter + best practice VTE prophylaxis
  • best practice VTE prophylaxis
Record updated
31 August 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Aged 18 years or older
  • Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study
  • For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure
  • For the prophylactic cohort, high risk VTE denoted by either:
  • Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma
  • For the therapeutic cohort, documented VTE per the following:
  • Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced
  • Requirement of temporary PE protection (8 weeks) based on clinical judgment
  • Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent

Who cannot take part

  • Previous IVC filter placement/retrieval within 6 months prior to randomization
  • Simultaneous participation in another investigative drug or device trial that has not reached its primary endpoint
  • Previously enrolled in a clinical investigation of the Adient filter
  • History of abdominal or pelvic radiation therapy
  • Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture)
  • Other co-morbid condition that, in the opinion of the Investigator, could limit the subject's ability to participate in or would affect the scientific integrity of the study
  • For Roll In, patient has advanced heart failure or recent (6 weeks) myocardial infarction. - - -
  • Renal insufficiency (GFR < 60) or requiring renal replacement therapy
  • Advanced heart failure is defined by NYHA class IV or AHA/ACC/HFSA stage D or LVEF < 40%. Subjects with MI diagnosed with ECG alone without MI history and symptoms are not excluded
  • Expected high VTE risk to extend beyond 8 weeks
  • Vena cava filter currently implanted
  • Confirmed positive blood cultures within the last 48 hours if there is bacteremia
  • Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated
  • Pregnant, lactating, or plans to become pregnant during investigation follow-up period
  • IVC effective diameter (D) <16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat)
  • Less than 7cm from inferior-most renal vein to the iliac vein confluence
  • Duplication of the IVC
  • Any thrombus or occlusion in IVC on pre-procedural CT cavogram
  • Life expectancy of < 12 months

Where in United States

  • University of Colorado Anschutz Medical CampusAurora, United States
  • IU Health University HospitalIndianapolis, United States

About the trial

What the trial wants to find out

The objective of the study is to evaluate the safety and efficacy of the Adient absorbable filter for the prevention of pulmonary embolism (PE: blood clot in the lungs). PE claims the lives of over 100,000 Americans each year, more than breast cancer, traffic fatalities and HIV combined.

Read full original descriptionShow less

Pharmaceutical anticoagulation (blood thinners) that reduce blood clot formation represent the standard of care for treating patients at risk for PE. However, for people who are temporarily unable to use anticoagulants, such as those who have suffered major trauma or those who are scheduled for surgical procedures, inferior vena cava (IVC) filters are used to help protect against PE. These blood filters prevent large blood clots that originate in the deep veins of the legs (deep vein thrombosis (DVT)) from reaching your lungs causing a potentially life-threatening PE.

Conventional metal IVC filters have been proven effective at reducing the incidence of PE, however, most require retrieval. If not retrieved within a timely manner (months), they can perforate the IVC, impale nearby organs with their barbed struts, and cause blood clots.

In contrast, the Adient absorbable filter traps blood clots similar to conventional metal IVC filters, but following the 8 week protection period, the filter itself breaks down into carbon dioxide and water. Hence no filter retrieval is required and complications are less likely due to the shortened indwell time. Once blood clots are trapped in the absorbable filter, the body's thrombolytic enzymes dissolve the clots within weeks while the filter itself resorbs in 6 to 8 months. The absorbable filter is braided from absorbable suture that has been proven safe over 4 decades.

The question being addressed with the randomized controlled trial portion is whether the placement of the absorbable filter in addition to current best practice PE prevention (sequential compression machines, compression stockings, and anticoagulants when indicated) significantly reduces the incidence of clinically significant PE in high risk subjects.

The absorbable filter will be indicated for the temporary prevention of PE in patients with transient high risk for venous thromboembolism (DVT and/or PE) with or without venous thromboembolic disease and as an enhancement to pharmaceutical anticoagulation and mechanical prophylaxis.

The 3 groups in the trial

  • TherapeuticTreatment being tested

    The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.

    Treatment: Adient absorbable filter + best practice VTE prophylaxis

  • Prophylactic - TestTreatment being tested

    The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.

    Treatment: Adient absorbable filter + best practice VTE prophylaxis

  • Prophylactic - ControlExisting treatment, for comparison

    The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.

    Treatment: best practice VTE prophylaxis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Pivotal Study With Randomized Controlled Prophylactic and Independent Therapeutic Cohorts to Evaluate the Safety and Efficacy of an Absorbable Vena Cava Filter for Pulmonary Embolism Prevention
Record updated
31 August 2023